---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034646"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2024-08-30T23:59:59+00:00"
generated_at: "2026-05-31T06:50:39.783356+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PowerUp Acquisition Corp. enters into definitive merger agreement with Aspire Biopharma valued at $316.8M

## Summary
- Consideration to Aspire stockholders: shares of New Aspire Common Stock valued at $316.8M less indebtedness and cash shortfall.
- Post-closing board: 7 directors (2 from PowerUp, 5 from Aspire); CEO and CFO to be Aspire's current officers.
- Closing conditions include shareholder approvals, SEC effectiveness of Form S-4, Nasdaq listing, and no material adverse effects.
- No termination fees; outside date of August 17, 2025 to consummate the transaction.
- PowerUp will domesticate from Cayman Islands to Delaware prior to closing.

## SEC filing metadata
- accession: 0001493152-24-034646
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2024-08-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315224034646/0001493152-24-034646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315224034646/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034646
- JSON: https://secwatch.observer/filing/0001493152-24-034646.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.